Circio converts bonds, increasing shares and capital

Circio Holding ASA announced the conversion of NOK 3,000,000 in convertible bonds held by Atlas Special Opportunities, LLC and Atlas Capital Markets, LLC. This conversion will result in the issuance of 4,975,399 new shares at a conversion price of NOK 0.60297 per share. Circio's share capital will increase by NOK 2,985,239.40 upon registration.

Following the completion and registration of this conversion, along with a NOK 2,500,000 conversion announced on October 6, the company's total share capital will stand at NOK 70,777,985.40. This will be divided into 117,963,309 shares, each with a nominal value of NOK 0.60.

Circio Holding ASA is a biotechnology company focused on developing circular RNA (circRNA) vector expression technology for next-generation nucleic acid medicine. The company's proprietary circVec platform aims to enhance gene and cell therapies, alongside its legacy immuno-oncology program, TG01, which targets RAS-mutated cancers and is currently in clinical trials.